Aaron Crookshank, MD
Critical Care Medicine · Marlton, NJNPI 1285875633
Payments from drug & device makers
Across 466 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$680
- Sanofi$640
- Harmony Biosciences LLC$557
- Regeneron Healthcare Solutions, Inc.$470
- plus $3K from 29 others
What the payments were for
- Consulting fees$2773%
- Food & beverage$7,30190%
- Education$5527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 125 | $1,516 |
| AstraZeneca | 64 | $1,256 |
| Jazz Pharmaceuticals Inc. | 31 | $680 |
| Sanofi | 34 | $640 |
| Harmony Biosciences LLC | 27 | $557 |
| Regeneron Healthcare Solutions, Inc. | 23 | $470 |
| Amgen | 18 | $337 |
| Boehringer Ingelheim | 21 | $302 |
| Biomerieux Inc | 1 | $277 |
| Actelion Pharmaceuticals US, Inc. | 18 | $277 |
| Mylan Specialty L.p. | 16 | $224 |
| Philips North America LLC | 12 | $194 |
| Inari Medical, Inc. | 1 | $143 |
| Insmed, Inc. | 8 | $125 |
| Verona Pharma, Inc. | 6 | $109 |
| ANI Pharmaceuticals, Inc. | 5 | $109 |
| Idorsia Pharmaceuticals US Inc | 7 | $105 |
| Grifols USA, LLC | 5 | $73 |
| Axsome Therapeutics, Inc. | 4 | $70 |
| Merck | 5 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| AbbVie(2 entities) | 3 | $61 |
| Genentech USA, Inc. | 4 | $60 |
| Bayer | 3 | $53 |
| Electromed, Inc. | 6 | $52 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $51 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| Novartis | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $39 |
| Vapotherm Inc | 1 | $29 |
| Eisai Inc. | 2 | $27 |
| Baxter Healthcare | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $21 |
| United Therapeutics Corporation | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,130 in reported general payments places this provider in the 85th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 428 | $326,715 |
| Dupixent PenDupilumab | 62 | $259,905 |
| OfevNintedanib Esylate | 24 | $249,989 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 136 | $101,230 |
| Breo ElliptaFluticasone/Vilanterol | 152 | $83,608 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $40,250 |
| EliquisApixaban | 53 | $34,087 |
| Incruse ElliptaUmeclidinium Bromide | 65 | $28,471 |
| Ambrisentan | 11 | $28,435 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 134 | $26,762 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $23,831 |
| Spiriva HandihalerTiotropium Bromide | 24 | $16,579 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 411 | $13,926 |
| Arnuity ElliptaFluticasone Furoate | 38 | $11,234 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $9,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,516 | $490,278759 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $302 | $283,43172 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,256 | $111,009159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Marlton
- Eric SztejmanMarlton$231K
- Jonathan GalliMarlton$128K
- Neha VagadiaMarlton$31K
- Emilio MazzaMarlton$29K
- Syed RiazMarlton$12K
- Rohit MalikMarlton$5K
- Angel RodisMarlton$4K
- Andrew SchiffMarlton$4K
- Roman KrolMarlton$4K
- Brian JaffeMarlton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.